Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria

Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical trial, CBS-HCY-01, for OT-58, a modified recombinant ... Read More